Evaluation of Lu AG13909 in Patients with Congenital Adrenal Hyperplasia

The primary objective of this clinical trial is to evaluate the efficacy and safety of **Lu AG13909** in participants diagnosed with **congenital adrenal hyperplasia**. This condition is a group of genetic disorders affecting the adrenal glands, leading to an imbalance in hormone production. Understanding the impact of Lu AG13909 on this condition is clinically significant as it may offer a new therapeutic option for managing hormone levels and improving patient outcomes. No secondary objectives are provided for this study.

The clinical trial involves a total of **24 participants** diagnosed with **congenital adrenal hyperplasia**. The study population includes both male and female subjects, with an age range spanning from **18 to 64 years**. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to gather data from a diverse group within the specified age range, ensuring a comprehensive understanding of the condition across different demographics.

The clinical trial is designed to evaluate the efficacy and safety of **Lu AG13909** in participants diagnosed with **congenital adrenal hyperplasia**. This study is structured as a randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thereby minimizing bias. The trial is set to commence recruitment on March 1, 2023, and is projected to conclude by December 31, 2027, encompassing a comprehensive duration to assess long-term outcomes.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, adherence to the treatment regimen, and any adverse events. These visits are integral to collecting data on the primary and secondary endpoints of the study.

The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather concluding data on the treatment's efficacy and safety profile. The expected length of participant involvement spans the entire trial duration unless specific conditions necessitate early termination. Such conditions may include significant adverse reactions, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding and management of congenital adrenal hyperplasia.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on March 1, 2023, with an estimated completion date of December 31, 2027. The trial is categorized under phase 7, indicating a specific stage in the clinical research process. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's effectiveness. The methodology for measuring efficacy will adhere to standard clinical trial protocols, ensuring that data is collected at predetermined intervals and analyzed using validated methods. The trial's design will ensure that efficacy assessments are conducted objectively and consistently throughout the study duration.